Looking for research-grade compounds?
Few compounds in bpc-157 peptide research carry as much reputation — and as much misunderstanding — as Body Protection Compound-157. For three decades it has been one of the most discussed “peps” in research circles, cited in more than fifty published studies and associated in lab settings with effects spanning tendon repair, gut protection, and angiogenesis. Yet until very recently, every one of those studies was preclinical — cells and animals, not people.
That changed, at least on paper, in September 2026, when the first randomized, placebo-controlled human trial of BPC-157 was registered on ClinicalTrials.gov. This profile walks through what researchers actually know: the proposed mechanisms, the state of the evidence, the regulatory reality, and what the new trial means for the field. Strictly research-use-only (RUO) framing throughout — nothing here is a recommendation for use.
BPC-157 stands for Body Protection Compound-157, a synthetic pentadecapeptide — a chain of exactly 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Researchers derived it from a protective protein found in human gastric juice, isolating the fragment most associated with the stomach lining’s remarkable ability to resist its own acid and digestive enzymes.
The compound was first characterized in the early 1990s by Predrag Sikiric’s research group at the University of Zagreb, Croatia. Their program produced the bulk of the BPC-157 literature over the following three decades, covering gastrointestinal, musculoskeletal, neurological, and cardiovascular models.
One structural feature made BPC-157 unusually versatile as a research tool: stability. Most peptides degrade within minutes in gastric acid, but BPC-157’s proline-rich structure survives in human gastric juice for more than 24 hours. That lets researchers study it across oral, injectable, and topical experimental models — a flexibility rare in peptide research. That versatility is part of why it remains a fixture of the research peptide catalog alongside growth-hormone secretagogues and metabolic compounds.
Unlike single-target peptides, BPC-157 is pleiotropic — preclinical work points to several interconnected pathways operating at once. Here is where the published literature stands.
The most consistently documented mechanism involves vascular endothelial growth factor receptor 2 (VEGFR2). A 2017 study by Hsieh et al. in the Journal of Molecular Medicine showed that BPC-157 promotes VEGFR2 internalization and downstream Akt-eNOS signaling, increasing vessel density in both cell culture and animal models (DOI: 10.1007/s00109-016-1488-y).
Why does that matter? Tendons and ligaments are poorly vascularized, and inadequate blood supply is a primary reason they heal slowly. By promoting angiogenesis — the formation of new blood vessels — BPC-157 addresses a bottleneck in connective-tissue repair that most studied compounds don’t target directly.
Closely connected to the VEGFR2 pathway is BPC-157’s influence on nitric oxide production. A 2020 study in Scientific Reports (PMC7555539) documented activation of endothelial nitric oxide synthase via VEGFR2/Akt signaling and reduction of the Caveolin-1 inhibitory interaction with eNOS.
The notable finding is bidirectionality: rather than simply driving nitric oxide up or down, BPC-157 appears to modulate the NO system depending on tissue context — a more sophisticated profile than a simple agonist effect.
Additional preclinical work describes activation of the FAK-paxillin pathway, which governs the migration and anchoring of repair cells into damaged tissue, and upregulation of growth hormone receptor expression in tendon and muscle cells — potentially amplifying downstream growth-factor signaling. Gene-level studies have also flagged JAK-2/Egr-1 signaling related to cell survival.
True to its gastric origins, BPC-157 has been studied in models of gastric ulceration and NSAID-induced mucosal damage, where it was associated with suppressed inflammatory cytokines (IL-6, TNF-α) and accelerated mucosal regeneration. Separate animal studies have reported interactions with dopamine and serotonin systems — an area still far from established.
Across the published record, BPC-157 has been investigated in models of:
What the literature does not contain, as of October 2026: a single completed, adequately powered human clinical trial. The entire evidence base is preclinical, much of it from one research group. That concentration is a real limitation researchers should weigh — independent replication is thinner than the citation count suggests.
In research circles the two are often discussed together — the “Wolverine” pairing in online slang. The comparison is instructive because it highlights how different two repair-focused “peps” can be:
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 fragment |
| Length | 15 amino acids | 43 amino acids |
| Origin | Gastric juice protein fragment | Thymosin Beta-4 fragment |
| Lead mechanisms (preclinical) | VEGFR2/angiogenesis, NO modulation, FAK-paxillin | Actin sequestration, cell migration |
| Gastric stability | High (>24 h in gastric juice) | Lower |
| FDA approval status | None | None |
| Human trial data | First RCT registered Sept 2026 (not yet recruiting) | Limited early-phase human data |
Both are investigational, neither is FDA-approved, and the pairing itself has never been tested in a controlled human trial — the nickname is community slang, not science. (Our peptide slang glossary decodes more of the community vocabulary researchers run into online.)
The honest summary of the human evidence: there is almost none. No completed Phase II or Phase III trials. No approved therapeutic use. The anecdotal reports circulating online — injury recoveries attributed to the compound — come from uncontrolled settings where physical therapy, time, and natural healing can’t be separated from any compound effect.
That is precisely why the September 2026 trial registration matters. Under identifier NCT07803250, the University of Arkansas registered a randomized, placebo-controlled trial of BPC-157 in patients recovering from rotator cuff surgery. The registry record itself states that BPC-157 “has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA.” The trial is listed as not yet recruiting, with a start date of January 1, 2027 — so there are no results to interpret. But the protocol is the first document of its kind: a pre-registered, controlled human design with defined endpoints. Researchers watching this space should watch it.
The regulatory picture needs stating plainly, because it is widely misreported:
For labs, the RUO designation is the governing framework — our overview of what research-use-only means covers why it matters for sourcing and handling.
BPC-157’s gastric stability is a research advantage, but standard peptide handling still applies. Lyophilized material should be stored cold and protected from moisture and freeze-thaw cycling — see our peptide storage best practices for the full protocol. And because the compound is unapproved and sold strictly for research, analytical verification is non-negotiable: every lot should arrive with a certificate of analysis, and researchers should know how to read one. Apex’s third-party COA testing program exists precisely because the RUO market’s quality variance is the field’s open secret.
Is BPC-157 FDA approved?
No. It is not approved for any indication in the US or, per FDA statements, in any country. A July 2026 advisory vote recommended it for a compounding list; that is not approval.
What is the established human dose?
There is none. No clinical trial has defined a safe or effective human dose, and animal doses cannot be translated directly. Any specific numbers circulating online are anecdotal, not evidence-based.
Why is it called the “Wolverine peptide”?
Community slang for its reputation in tissue-repair research, often paired with TB-500. The nickname is not a scientific or regulatory term.
How does it differ from TB-500?
Different origin, different lead mechanisms (angiogenic/VEGFR2 signaling vs. actin-based cell migration), and different evidence bases. See the comparison table above.
What should I check before sourcing BPC-157 for research?
A third-party certificate of analysis with HPLC purity and mass-spec identity confirmation, from a supplier that tests every lot. Our COA guide walks through reading one.
BPC-157 is one of the most studied investigational peptides in the RUO space — and simultaneously one of the least proven in humans. Thirty years of preclinical work sketch plausible, multi-pathway mechanisms for tissue repair, but plausibility is not proof. The registered University of Arkansas trial is the field’s first real test. Until it reads out, the responsible position is the evidence-based one: interesting biology, no human data, strictly research use.
Researchers studying the BPC-157 and TB-500 pairing discussed above can explore ready-made peptide blends for combination protocols.
Related in the Apex shop: BPC-157 research peptide — supplied strictly for laboratory research use.
Research Use Only disclaimer: BPC-157 is an investigational compound sold strictly for laboratory research purposes. It is not approved by the FDA for any use, has not been evaluated for safety or efficacy in humans, and is not intended for human or veterinary use. Nothing in this article constitutes medical advice.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
